Management of hypertension in COVID-19  

作　　者：Daniel Antwi-Amoabeng Bryce D Beutler Alastair E Moody Zahara Kanji Nageshwara Gullapalli Christopher J Rowan 

机构地区：[1]Department of Internal Medicine,Reno School of Medicine,University of Nevada,Reno,NV 89052,United States [2]Department of Anesthesiology,University of Utah,Salt Lake City,UT 84132,United States [3]Renown Institute for Heart and Vascular Health,Reno,NV 89512,United States

出　　处：《World Journal of Cardiology》2020年第5期228-230,共3页世界心脏病学杂志（英文版）（电子版）

摘　　要：The ACE2 receptor plays a central role in severe acute respiratory syndrome coronavirus 2 host cell entry and propagation.It has therefore been postulated that angiotensin converting enzyme inhibitors and angiotensin receptor blockers may upregulate ACE2 expression and thus increase susceptibility to infection.We suggest that alternative anti-hypertensive agents should be preferred among individuals who may be exposed to this increasingly common and potentially lethal virus.

关 键 词：Angiotensin converting enzyme inhibitor Angiotensin receptor blocker CARVEDILOL Coronavirus disease-19 COVID-19 SARS-CoV-2 VERAPAMIL 

分 类 号：R563.1[医药卫生—呼吸系统] R544.1[医药卫生—内科学]